Cell News and Research

RSS

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.

8 Dec 2009

Gene positions may offer a new method of cancer diagnosis

Certain genes switch their nuclear position in tumor cells, offering a potential new method of diagnosing cancer, say researchers from the National Cancer Institute. The study by Meaburn et al. will be published online December 7, 2009 (www.jcb.org) and in the December 14, 2009 print issue of the Journal of Cell Biology (JCB).

8 Dec 2009

Study: Besides nerves, skin has a unique sensory system

The human sensory experience is far more complex and nuanced than previously thought, according to a groundbreaking new study published in the December 15, 2009 issue of the journal Pain (http://www.painjournalonline.com/article/S0304-3959%2809%2900526-0/abstract).

8 Dec 2009

New genetic approach may hold promise for sickle cell disease

A new genetic approach to treating sickle cell disease is showing promising results in mice, report researchers from Children's Hospital Boston. By inactivating a gene they previously discovered to be important in the laboratory, they were able to boost production of a healthy fetal form of hemoglobin in the mice, potentially compensating for the defective adult hemoglobin that causes red blood cells to "sickle" and obstruct blood flow.

8 Dec 2009

Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.

8 Dec 2009

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to SAR3419 – administered as a single agent – among patients with B-cell non-Hodgkin's lymphoma that is refractory to treatment with rituximab (Rituxan®).

8 Dec 2009

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

Gentium S.p.A. today announced final clinical trial results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease (VOD), which were presented at the American Society of Hematology Conference (ASH) in New Orleans.

8 Dec 2009

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of REVLIMID plus low-dose dexamethasone (Rd) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

8 Dec 2009

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

In addition to data released in late November, ChemoCentryx, Inc., announced today more data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease.

8 Dec 2009

JAK2 inhibitor can control myelofibrosis, report researchers

A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Turmeric and pepper may play a role in preventing breast cancer

A new study finds that compounds derived from the spices turmeric and pepper could help prevent breast cancer by limiting the growth of stem cells, the small number of cells that fuel a tumor's growth.

8 Dec 2009

Defibrotide drug effective against hepatic veno-occlusive disease

Defibrotide, a novel drug which modulates the response of blood vessels to injury, was markedly more effective than standard treatment in post-stem cell transplant patients with hepatic veno-occlusive disease, a life threatening toxicity of transplant caused by blockages in tiny blood vessels of the liver, according to a study led by Dana-Farber Cancer Institute scientists.

8 Dec 2009

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Novo Nordisk A/S and ZymoGenetics, Inc. today announced an agreement where Novo Nordisk in-licenses a fully-human anti-IL21 monoclonal antibody (IL-21 mAb) developed by ZymoGenetics, as well as broad intellectual property rights covering IL-21 mAb and the development of other IL-21 antibodies.

From Novo Nordisk 8 Dec 2009

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells — a process that potentially could be used against a range of chronic viral diseases.

8 Dec 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented today at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.

8 Dec 2009

Abstracts on very small embryonic-like stem cells presented at ASH annual meeting

NeoStem, Inc., which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need and holds the exclusive, worldwide license to VSEL(TM) technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that an abstract authored by NeoStem-affiliated scientists was presented in a poster presentation at the prestigious American Society of Hematology (ASH) Annual Meeting in New Orleans on December 5, 2009.

8 Dec 2009

Animal study demonstrates how whole chromosome changes cause cancer

Mayo Clinic researchers have proven the longstanding theory that changes in the number of whole chromosomes -- called aneuploidy -- can cause cancer by eliminating tumor suppressor genes.

8 Dec 2009

Amgen announces results from first Phase 1/2 study of Nplate

Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).

8 Dec 2009

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Monday, Dec. 7 (Ernest N. Morial Convention Center, Room 343-345, 5:15 pm CT).

8 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

Cell News and Research

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Gene positions may offer a new method of cancer diagnosis

Study: Besides nerves, skin has a unique sensory system

New genetic approach may hold promise for sickle cell disease

Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

JAK2 inhibitor can control myelofibrosis, report researchers

Turmeric and pepper may play a role in preventing breast cancer

Defibrotide drug effective against hepatic veno-occlusive disease

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Abstracts on very small embryonic-like stem cells presented at ASH annual meeting

Animal study demonstrates how whole chromosome changes cause cancer

Amgen announces results from first Phase 1/2 study of Nplate

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

CAM314 randomized Phase 3 clinical trial results released

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News